20:25 , Aug 21, 2019 |  BC Innovations  |  Distillery Therapeutics

Targeting CAD or DHODH to inhibit pyrimidine synthesis for glioblastoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Blocking pyrimidine synthesis via inhibition of CAD or DHODH, an enzyme downstream CAD, could treat glioblastoma. In patients, high tumor expression of a pyrimidine metabolism gene signature was associated...
23:17 , Jul 12, 2019 |  BC Extra  |  Financial News

HitGen joins growing Shanghai IPO queue

The Shanghai Stock Exchange accepted an application from HitGen this week to list on its new science and technology innovation board. The small molecule discovery company proposed to sell at least 40 million shares and...
23:28 , Jun 26, 2019 |  BC Innovations  |  Distillery Therapeutics

Induction of NFE2L2 activity for Alzheimer's disease

DISEASE CATEGORY: Neurology INDICATION: Alzheimer's disease (AD) Inducers of NFE2L2 activity could help treat AD. Postmortem brain tissue from seven AD patients had lower NFE2L2 protein levels than tissue from seven control donors, and low...
00:02 , Jun 26, 2019 |  BC Extra  |  Company News

June 25 Company Quick Takes: Conatus restructuring; plus Almirall-Dermira, Acer, Glenmark and more

Conatus cuts headcount by 40% to extend runway  Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) said it will lay off 40% of its staff and suspend development of caspase 1 inhibitor CTS-2090 in a bid to extend its...
22:41 , Jun 20, 2019 |  BC Innovations  |  Targets & Mechanisms

Moving beyond the active site: why allostery is newly in fashion

A new crop of companies is creating tools to systematize development of allosteric protein inhibitors, finally moving industry beyond the one-off compounds that have been found by accident. Allosteric pockets on proteins have long been...
18:38 , Jun 2, 2019 |  BC Extra  |  Company News

Aslan’s change of course on eczema asset brings flexibility for future deals

Aslan's decision to restructure an existing deal with CSL for atopic dermatitis candidate ASLAN004, extending the partnership's scope to give the biotech full commercial rights, is part of Aslan's broader intention to gain flexibility for...
20:54 , May 20, 2019 |  BC Innovations  |  Distillery Therapeutics

Aubagio and other DHODH inhibitors as epilepsy therapies

DISEASE CATEGORY: Neurology INDICATION: Epilepsy Patient sample, cell culture and mouse studies suggest inhibiting DHODH could help treat epilepsy. Metabolic modeling of transcriptome data from the cortex and hippocampus of epilepsy patients and two rat...
19:15 , May 10, 2019 |  BioCentury  |  Emerging Company Profile

HopeMed: Targeting PRLR for chronic diseases

HopeMed spun out of Peking University last month with a mAb against the prolactin receptor from Bayer that could provide a safe alternative to competing therapies for endometriosis and alopecia. Hope Medicine Inc. has exclusive...
21:48 , Apr 2, 2019 |  BC Innovations  |  Distillery Therapeutics

Conbriza bazedoxifene for MS and other demyelinating diseases

DISEASE CATEGORY: Autoimmune disease; neurology INDICATION: Multiple sclerosis (MS); neurology Cell culture and mouse studies suggest Conbriza bazedoxifene could help treat MS and other demyelinating diseases. In oligodendrocyte precursor cells (OPCs) derived from a human...
18:37 , Mar 29, 2019 |  BC Week In Review  |  Company News

Almirall and HitGen partner for atopic dermatitis drug discovery

Dermatology company Almirall partnered with discovery company HitGen to identify oral small molecules against undisclosed targets for moderate-to-severe atopic dermatitis. Almirall S.A. (Madrid:ALM) will provide screening material and HitGen Ltd. (Chengdu, China) will use its...